Since the enactment of the Hatch-Waxman Act in 1984, courts have held that brand companies can sue generics wherever they plan on making sales, which is everywhere in the U.S. In practice, most suits have been filed in Delaware and New Jersey, with suits against multiple generic companies over the same drug consolidated in one proceeding.
In November 2020, the Federal Circuit upended this settled practice when it issued its opinion in Valeant Pharmaceuticals v. Mylan Pharmaceuticals, No. 19-2402 (Fed. Cir. 2020), holding that venue is not established by contemplated future acts of ...
Blog Editors
Recent Updates
- A Potential New Path for School Districts to Settle Child Victims Act Cases: New York’s Limited Finance Law Amended to Assist School Districts
- State Cannot Immunize Parties from Federal Civil Liability - SCOTUS Today
- Good Faith, Bad Timing: Musk, Privilege, and the Price of the Advice-of-Counsel Defense
- Term Begins with Easy Unanimity, a Condition Soon to Be Forgotten - SCOTUS Today
- Service and Justice: Veterans in Law – Speaking of Litigation Video Podcast